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Abstract
Background: The objective of this study is to compare lactate levels between users and non-users of diabetes medications
under the hypothesis that the level of lactate is a marker of oxidative capacity.
Methods: The cross-sectional data of 493 participants aged 61–84 with type 2 diabetes who participated in the
Atherosclerosis Risk in Communities Carotid MRI study were analyzed using survey weighted linear regression.
Results: Median plasma lactate level was 8.58 (95% CI: 8.23, 8.87) mg/dl. Comparing users of diabetic medications with non-
users, thiazolidinedione use was significantly associated with lower lactate level (7.57 (6.95–8.25) mg/dL vs. 8.78 (8.43–9.14)
mg/dL), metformin use with a slightly higher lactate level (9.02 (8.51–9.58) mg/dL vs. 8.36 (7.96–8.77) mg/dL), and
sulfonylurea and insulin use were not associated with lactate level. After adjustment for demographic and lifestyle factors,
the plasma lactate level for thiazolidinedione users was 15.78% lower than that for non-users (p,0.001). Considering use of
each medication separately and in combination did not change the results.
Conclusion: In conclusion, thiazolidinedione use was associated with lower plasma lactate level compared to non-use and
metformin use was only marginally associated with a slightly higher lactate level. These results are consistent with the
previously demonstrated effects of diabetes medications on oxidative metabolism. Further investigation of the role that
diabetes medications play in improvement of oxidative metabolism is warranted.
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Introduction
Oxidative capacity is the balance between the body’s demand
for energy and the ability to provide that energy through oxidative
pathways. The use of lactate as a marker of systemic imbalance in
oxygen demand and availability allows for the relatively new
emergence of population based studies on oxidative capacity [1–
3]. Decreased oxidative capacity, or mitochondrial dysfunction, is
associated with increased insulin resistance, although the causal
direction of this association is still in question [4–7]. Recent work
in the Atherosclerosis Risk in Communities(ARIC) Carotid MRI
study used higher blood lactate as an indicator of reduced
oxidative capacity to investigate this association [1].
The relationship between oxidative capacity and insulin
resistance leads to the hypothesis that interventions that lower
insulin resistance may also impact oxidative capacity. The
relationship of the biguanides with lactate level has been well-
studied due to the clinical concern about lactic acidosis. While a
recent Cochrane review suggests that patients taking metformin do
not have higher lactate levels, only a few studies with small sample
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sizes were available and an increase in lactate level would be
consistent with some of metformin’s physiologic effects [8].
Specifically, lactate is the primary precursor for gluconeogenesis.
Since metformin decreases hepatic gluconeogenesis, it decreases
lactate utilization and potentially increases lactate levels [9].
In contrast, the direct effect of other diabetes medications on
lactate levels is largely unknown. Thiazolidinediones (TZDs), for
example, may influence lactate levels through prevention of
gluconeogenesis in the liver like metformin, as well as through
increases in oxidative phosphorylation in skeletal muscle and
adipose tissue [9,10]. TZDs are also known to increase oxygen
availability more generally by decreasing adipocyte size and
increasing vasodilatation [9,10]. Furthermore, TZDs significantly
increased exercise capacity as measured by Vo2max in a clinical
trial [11]. These effects on increased oxidative capacity in both
adipose tissue and skeletal muscle may result in an overall decrease
in plasma lactate levels. Insulin may also increase oxidative
capacity through stimulation of mitochondrial biogenesis and
increased vasodilatation [6,12–15]. Based on the differing effects of
medication classes on oxidative pathways, each class of diabetes
medication should have a different association with lactate levels.
To test these hypotheses, we investigated the difference in plasma
lactate levels between users and non-users of diabetes medications
among ARIC Carotid MRI Study participants.
Materials and Methods
Study population
The original ARIC study has been described in detail elsewhere
[16]. This study used a subset of the ARIC Carotid MRI ancillary
study, which included 2066 of the original ARIC participants,
oversampled for high carotid intima-media thickness (IMT) [1,17].
The primary goal of the ARIC CAR-MRI ancillary study was to
identify factors related to carotid atherosclerosis measured with
carotid MRI. Given the expense and inconvenience of MRI
assessment, the number of ARIC participants required was
minimized by oversampling patients with high IMT levels, thereby
generating a sufficient range of IMT levels for analyses. Since the
Carotid MRI study oversampled participants with high IMT, our
sample is over represented by these participants. Given the known
sampling probability ARIC Carotid-MRI study participants,
however, we can adjust all traditional analyses (such as linear
regression in this case) to reflect the distribution of factors in the
entire ARIC cohort, with a measure of uncertainty as reflected in
the confidence intervals. Therefore, we incorporated inverse
probability weights in all analyses to compensate for the sampling
design and provide unbiased estimates that reflect the entire ARIC
population. This subset was chosen as plasma lactate was available
for these participants through an ancillary study. Lactate
measurements were not available for the rest of the cohort.
Participants missing fasting plasma lactate levels or other variables
of interest as well as those with a body mass index less than
18.5 kg/m2 were excluded from the lactate ancillary study subset
(n = 182). Only participants with type 2 diabetes, determined at
the Carotid MRI visit by a fasting blood glucose higher than
126 mg/dL, previous diagnosis, or treatment, were included
(n = 496). Finally, those missing data on diabetes medication use
were excluded (n = 3). The final sample size for this analysis
includes 493 participants aged 61 to 84.
Ethics Statement
The study was approved by the institutional review board of the
Johns Hopkins Bloomberg School of Public Health (IRB No:
H.34.04.08.16.A1) and all participants provided full written
consent.
Exposure
Diabetes medication use was defined as use of any diabetes
medication in the four weeks prior to the Carotid MRI study clinic
visit and is based on review of medication containers brought to
the study visit by participants. Similarly, use of each specific class
of diabetes medications (TZDs, metformin, insulin, and sulfonyl-
urea) was defined as any use of that specific medication type in the
previous four weeks assessed by container review. For the primary
analysis, participants could be taking more than one type of
diabetes medication and the comparison group is participants not
taking that medication type.
Outcome
Measurement and validation of plasma lactate levels in the
ARIC Carotid MRI Study has been described previously [1].
Briefly, plasma lactate concentrations were measured on a Roche
Hitachi 911 auto-analyzer using an enzymatic reaction whereby
lactate was converted to pyruvate and hydrogen peroxide, which
was then measured through the generation of dye by the reaction
of hydrogen peroxide and peroxidase. Reliability of repeated
plasma lactate measurements in this sample was high (reliability
coefficient = 0.93) [1].
Covariates
Potential confounding variables of interest included age, sex,
race, education level (completed high school or not), body mass
index (BMI), waist to hip ratio, leisure-time physical activity using
the Baecke questionnaire [18], smoking, alcohol consumption,
markers of kidney function (creatinine and glomerular filtration
rate) and insulin resistance (triglyceride/HDL ratio). Demographic
variables were taken collected at baseline (ARIC visit 1). All other
data were collected during the Carotid MRI Study visit.
Statistical analysis
Due to the ARIC Carotid MRI sampling strategy, the basic
characteristics of the study sample were reported as stratified
sample-weighted means and linearized standard errors by use of
each diabetes medication. Plasma lactate level was log transformed
to account for deviations from the normal distribution and to
improve model fit. Lactate level was reported as geometric means
and 95% confidence intervals and differences in log lactate level
were reported as back transformed percent differences and 95%
confidence intervals. Multivariable analysis was performed using
linear regression on cross-sectional data using stratified sample
weights that account for the sampling scheme in the Carotid MRI
Study. These weights include consideration for oversampling of
intima-media thickness by study site and effectively remove the
influence of oversampling for high IMT [1]. Results from linear
regression on log lactate level were also reported as back
transformed percent differences and 95% confidence intervals.
Models were adjusted first for demographic factors (age, sex, race,
and education) as well as physical activity level and body mass
index. Primary models were checked for sensitivity to smoking and
alcohol consumption. Additional sensitivity analyses were con-
ducted to determine whether substituting waist to hip ratio for
body mass index, adjusting for markers of kidney function such as
creatinine and glomerular filtration rate, or adjusting for
overlapping medication use influenced the results. All analyses
were performed using STATA 11 [19].
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Results
Overall median plasma lactate level in the study sample was
8.58 (95% CI: 8.23, 8.87) mg/dl compared to 7.13 (95% CI: 7.00,
7.27) mg/dl in the non-diabetic cohort. Participant characteristics
by diabetes medication use are displayed in Table 1. In unadjusted
analyses, metformin use was marginally associated with higher
mean plasma lactate level (percent difference = 8.0%, P = 0.05)
and thiazolidinedione (TZD) use was associated with lower lactate
levels (percent difference = 213.8%, P = 0.002), but other diabetes
medication use was not associated with differences in lactate
(Table 1). The results were similar after simultaneous adjustment
for age, sex, race, education level, physical activity, and body mass
index (Figure 1). Results were also similar when waist to hip ratio
was used instead of body mass index (data not shown) and after
further adjustment for smoking status, alcohol consumption,
markers of kidney function (creatinine and glomerular filtration
rate) and insulin resistance (triglyceride/HDL ratio), and pre-
existing co-morbidities (stroke, coronary heart disease, and heart
failure) (Table 2). Adjustment for other diabetes medication use
also produced similar results (data not shown). In analyses
restricted to participants taking only one type of diabetes
medication compared to those taking no diabetes medication,
the association between TZD use and lower lactate levels was
more evident (Figure 2). Among those who used both metformin
and TZDs, the association of TZD use with lactate level was
attenuated.
Discussion
In this cross-sectional analysis, TZD use was associated with
lower levels of plasma lactate, while metformin use was associated
with marginally higher levels. Although insulin use was associated
with marginally lower lactate level, this association was not
statistically significant. Sulfonylurea use was not associated with a
difference in blood lactate level.
When oxidative pathways are limited, either through insuffi-
cient oxygen availability or mitochondrial dysfunction, lactate
production increases due to ongoing anaerobic glycolysis. Clini-
cally, plasma lactate is routinely used to assess poor tissue
oxygenation associated with conditions such as ischemic bowel
and circulatory collapse. In the presence of these disorders, plasma
lactate commonly rises to values .36 mg/dl. For 95.7% of ARIC
CAR-MRI participants, however, blood lactate level was within
the normal range (4.5–19.8 mg/dl) [1,20].
The association of metformin with marginally higher lactate
levels is consistent with the effects of metformin on glucose
metabolism and with a large meta-analysis by Salpeter et al. [8]
Salpeter et al. showed that when compared to those not taking
metformin, metformin users had a slightly higher level of lactate
that was borderline statistically significant. Metformin’s impact on
blood glucose levels is primarily through a reduction in hepatic
gluconeogenesis. Since lactate is the primary gluconeogenic
precursor, decreased gluconeogenesis would result in higher
plasma lactate levels, assuming lactate production is unchanged.
In contrast to metformin, TZDs are associated with lower
lactate levels, which may be due to their impact on oxygen
availability in adipose tissue. One of TZD’s major effects is to
Figure 1. Adjusted percent differences in plasma lactate in the ARIC Carotid MRI Study. Adjusted differences in plasma lactate (vs non-
users of diabetes medications) in users of thiazolidinediones, Insulin, Sulfonylureas, and Metformin in those with type 2 diabetes in the ARIC Carotid
MRI Study: Percent differences and 95% confidence intervals. Adjusted for age, sex, race, and education, sport and leisure activity, and body mass
index.
doi:10.1371/journal.pone.0051237.g001
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increase the number of small adipocytes, which are less insulin
resistant than more mature fat cells [10]. Furthermore, their
interiors are less hypoxic since oxygen can more easily diffuse
across the shorter distance from cell surface to the cell’s center
[21,22]. Since adipose tissue is a major source of lactate in insulin
resistance and obesity [23,24], TZD’s impact on the proliferation
of small, insulin-sensitive adipocytes may explain a major portion
of their impact on lactate levels. Furthermore, TZDs tend to
increase adipose tissue blood flow though vasodilatation, further
increasing oxygen availability.
TZDs may also impact resting oxygen utilization and lactate
production in skeletal muscle. As with adipose tissue, TZDs
increase oxygen availability in muscle though vasodilatation.
Furthermore, Regensteiner et al have shown that TZD use is
associated with increased exercise capacity in individuals with type
2 diabetes, suggesting that impairments in exercise capacity seen
with type 2 diabetes may be due to mitochondrial dysfunction
[11]. They further suggest that the improvements in exercise
capacity with TZD use may be due to TZD’s effects on oxidative
capacity. This study supports these findings through the demon-
stration of lower resting plasma lactate in patients taking TZDs.
Given that TZDs exhibit multiple mechanisms that could result in
lower lactate levels, the association of TZD use with lower lactate
levels is consistent with the expected overall effect of TZDs.
This study has some limitations. The cross-sectional design
limits investigation of temporality. Repeated measurements of
plasma lactate and longitudinal data on medication use were not
available for this analysis. Despite adjustment for markers of
kidney function and insulin resistance, these associations may be
confounded by factors related to the indication of the medications
assessed, since this study did not adjust for the duration since
diagnosis of diabetes or severity of diabetes progression. Moreover,
direct measurements of oxygen availability, mitochondrial capac-
ity, and demand for oxidative phosphorylation were also
unavailable, requiring this study to rely on lactate as a marker of
the mismatch between supply of ATP through oxidative
phosphorylation and demand. Despite using plasma collected at
rest and adjusting for BMI, smoking, and heart failure, we were
unable to determine whether oxygen availability or mitochondrial
capacity were primarily responsible for lactate variation. Addi-
tionally, it was not possible to investigate the association of lactate
level with specific diabetes medications within a medication class
separately. Since different TZDs have been shown to have slightly
different mechanisms and side effects, it would be useful to know if
the association with lactate level is consistent across different
TZDs.
The strengths of this study include a community-based sample
of older adults with type 2 diabetes who had measured plasma
lactate levels and confirmed medication use. This study also has
the advantage of being able to adjust for a large number of
covariates. The lactate measurements used in the ARIC Carotid
MRI study have been previously reported to have high reliability
[1].
The association between TZD use and lower lactate level in this
study reinforces the connection between insulin resistance and
oxidative processes. While the clinical significance of a lower
lactate level within the normal range is unknown, this study
provides cross-sectional but population-based support for the idea
Figure 2. Effect of medication combinations on percent differences and 95% confidence intervals in serum lactate level. Effect of
medication combinations on percent differences and 95% confidence intervals in serum lactate level (mg/dl) among persons with type 2 diabetes in
the ARIC Carotid MRI Study. All comparisons based on a model containing age, sex, race, education, sport and leisure activity, and body mass index.
Diabetes medication use was constructed as a factor variable with mutually exclusive groups representing each medication separately and in
combination. All groups are compared to no diabetes medication use. Not all combinations are shown.
doi:10.1371/journal.pone.0051237.g002
Diabetes Medication Use and Lactate Level




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diabetes Medication Use and Lactate Level
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e51237
that TZDs may increase oxidative capacity [11]. Furthermore,
TZDs ability to improve insulin sensitivity may be enhanced by
their impact on oxidative utilization. The association of TZD use
with lower lactate level supports the interest in developing new
PPAR-gamma agonists and TZD-like drugs for the treatment of
diabetes. Further investigation of the role that diabetes medica-
tions play in mechanisms of insulin resistance and oxidative
metabolism may provide insight into diabetes treatment.
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